Skip to main content
Premium Trial:

Request an Annual Quote

Promega to Co-Develop Drug-Screening Assays With Chinese Institute

NEW YORK (GenomeWeb News) — Promega and China’s Guangzhou Institute of Biomedicine and Health plan to co-develop drug-screening assays, the company said today. 
 
Under the agreement, GIBH researchers will use Promega’s drug-screening assays to develop tests for Cytochrome P450, Kinase, and GPCR profiling.
 
Promega said GIBH, which is part of the Chinese Academy of Sciences, will use the assays for their own research and will offer them through contracts to other companies.
 
Financial terms of the agreement were not released.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.